LJPC
La Jolla Pharmaceutical Company
LJPC
LJPC
Delisted
LJPC was delisted on the 19th of August, 2022.
About: La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Employees: 66
Charts implemented using
Lightweight Charts™